Zimmer Biomet Holdings Inc
NYSE:ZBH
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
101.77
132.61
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZBH stock under the Base Case scenario is 152.24 USD. Compared to the current market price of 108.41 USD, Zimmer Biomet Holdings Inc is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zimmer Biomet Holdings Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZBH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Zimmer Biomet Holdings Inc. is a leading global medical device company renowned for its innovative solutions in the musculoskeletal health sector. Founded in 1927 and headquartered in Warsaw, Indiana, the company specializes in orthopedic implants, including those used in joint reconstruction and spinal surgery, as well as dental and neuromuscular devices. With a commitment to enhancing the quality of life for patients worldwide, Zimmer Biomet leverages cutting-edge technology and extensive research to develop products that cater to an aging population and a growing demand for minimally invasive surgical options. As the healthcare landscape evolves, Zimmer Biomet’s adaptable business strateg...
Zimmer Biomet Holdings Inc. is a leading global medical device company renowned for its innovative solutions in the musculoskeletal health sector. Founded in 1927 and headquartered in Warsaw, Indiana, the company specializes in orthopedic implants, including those used in joint reconstruction and spinal surgery, as well as dental and neuromuscular devices. With a commitment to enhancing the quality of life for patients worldwide, Zimmer Biomet leverages cutting-edge technology and extensive research to develop products that cater to an aging population and a growing demand for minimally invasive surgical options. As the healthcare landscape evolves, Zimmer Biomet’s adaptable business strategy and focus on strategic partnerships position it favorably to capture new market opportunities and drive future growth.
For investors, Zimmer Biomet represents a compelling choice within the healthcare sector due to its strong market presence and consistent revenue generation. The company operates in a resilient industry characterized by ongoing technological advancements and a steady demand for orthopedic procedures driven by demographic trends. Zimmer Biomet has strategically streamlined its operations, enhancing operational efficiencies and reducing costs, which are promising signs of financial health. With a robust pipeline of innovative products and a focus on expanding its global footprint, Zimmer Biomet is well-equipped to navigate the complexities of the healthcare market and deliver sustainable value to its shareholders over the long term.
Zimmer Biomet Holdings, Inc. is a global leader in musculoskeletal healthcare, specializing in the design, development, and manufacture of orthopedic reconstructive products, as well as other medical devices. The company operates through several core business segments, each focusing on different aspects of orthopedic and musculoskeletal care. Here are the primary segments:
-
Orthopedic Reconstruction: This segment focuses on products designed for joint replacement surgeries, including hip and knee replacements. Zimmer Biomet offers a wide range of implants and related products for both primary and revision surgeries.
-
Surgical: This segment encompasses a variety of products used in surgical procedures, including surgical instruments and equipment. It supports a range of surgeries beyond orthopedics, including spine, trauma, and craniomaxillofacial surgeries.
-
Sports Medicine: Zimmer Biomet provides products related to soft tissue repair and other sports-related injuries. This includes arthroscopic devices, fixation products, and biologics for repairing ligaments and tendons.
-
Dental: The dental segment focuses on implants and related products for dental restoration and rehabilitation. Zimmer Biomet offers a portfolio of solutions for dental professionals to restore patients’ oral health.
-
Craniomaxillofacial: This segment includes products for reconstructive surgeries relating to the skull, jaw, and face. Zimmer Biomet provides implants, plates, and screws designed for the treatment of trauma and congenital deformities.
-
Bone Healing and Regeneration: This segment covers advanced technologies such as external fixation systems and bone grafting products designed to promote bone healing in traumatic injuries and reconstructive procedures.
Each of these segments plays a significant role in Zimmer Biomet's overall strategy, allowing the company to cater to various facets of orthopedic care and maintain a comprehensive portfolio in musculoskeletal health solutions.
Zimmer Biomet Holdings, Inc. is a prominent player in the orthopedic medical devices sector, known for its innovative products and extensive market reach. Here are several unique competitive advantages that Zimmer Biomet may hold over its rivals:
-
Comprehensive Product Portfolio: Zimmer Biomet offers a wide range of orthopedic products, including joint reconstruction, spine, craniomaxillofacial, dental, and surgical products. This diverse portfolio allows them to meet various clinical needs and establish strong relationships with healthcare providers.
-
Strong Brand Reputation: With a legacy dating back several decades, Zimmer Biomet has built a trusted brand known for quality and innovation. This reputation can significantly influence buying decisions in the healthcare sector.
-
Investment in Research and Development: Zimmer Biomet invests heavily in R&D to develop advanced technologies, such as robotic-assisted surgery and 3D printing. Their commitment to innovation helps maintain a competitive edge by offering cutting-edge solutions that improve patient outcomes and surgical efficiency.
-
Global Distribution Network: The company possesses a robust global distribution network, allowing it to efficiently deliver products to healthcare providers worldwide. This extensive reach is vital in gaining market share in diverse regions.
-
Strong Relationships with Healthcare Professionals: Zimmer Biomet focuses on building partnerships with surgeons and healthcare organizations, providing education and training on their product lines. This engagement fosters loyalty and a preference for their solutions.
-
Collaborative Partnerships and Acquisitions: The company's strategy of forming collaborations and making strategic acquisitions allows it to expand its product offerings and market presence quickly. These partnerships can also enhance their innovation pipeline.
-
Focus on Value-Based Healthcare: Zimmer Biomet is increasingly adapting to the shift towards value-based healthcare, offering solutions that emphasize improved patient outcomes and cost-effectiveness. This aligns with the current trends in the healthcare industry and can make their products more appealing to providers.
-
Advanced Manufacturing Capabilities: The company's facilities are equipped with advanced manufacturing technologies, resulting in high-quality production and the ability to scale operations effectively to meet market demands.
-
Regulatory Expertise: Zimmer Biomet has extensive experience navigating the complex regulatory landscape in the medical device industry. This expertise allows the company to expedite product approvals and bring innovations to market faster than some competitors.
-
Financial Strength and Stability: As a well-established company, Zimmer Biomet benefits from financial stability, allowing for sustained investment in growth initiatives, R&D, and potential acquisitions that smaller rivals may struggle to manage.
These competitive advantages establish Zimmer Biomet as a formidable player in the orthopedic market, enabling it to respond effectively to industry challenges and customer needs.
Zimmer Biomet Holdings Inc., as a major player in the orthopedic medical device sector, faces a range of risks and challenges that could affect its operations and financial performance in the near future. Here are some key risks and challenges to consider:
-
Regulatory Challenges: The medical device industry is heavily regulated. Changes in regulations or delays in approvals for new products can hinder innovation and market entry.
-
Market Competition: The orthopedic market is highly competitive, with numerous players ranging from large multinational corporations to smaller companies. Zimmer Biomet must continuously innovate to maintain its market share and respond to competitive pricing pressures.
-
Supply Chain Disruptions: Global supply chain issues can impact the availability and cost of raw materials and components, which can lead to delays in product delivery and increased operational costs.
-
Technological Advancements: Rapid advancements in med-tech and surgical techniques require Zimmer Biomet to invest significantly in R&D. Failure to keep pace with technological trends could result in losing market relevance.
-
Healthcare Reforms: Changes in healthcare policies, reimbursement rates, and payment models, particularly in the U.S., can affect hospital spending on medical devices and impact sales.
-
Litigation Risks: The company is susceptible to legal challenges related to product liability, patent infringements, and regulatory compliance. Ongoing lawsuits can lead to substantial financial liabilities and damage to reputation.
-
Economic Conditions: Economic downturns and uncertainties can affect healthcare spending. Hospitals may delay capital expenditures on new devices, directly impacting sales.
-
Product Recalls: Issues related to product quality or performance may lead to recalls, which can damage brand reputation and result in significant costs.
-
International Geopolitical Risks: Global operations expose Zimmer Biomet to geopolitical tensions, trade disputes, and varying economic conditions across markets which can affect sales and operational stability.
-
Talent Acquisition and Retention: The ability to attract and retain skilled personnel, particularly those in research, engineering, and sales, is critical for continued success. A shortage of talent could stifle growth and innovation.
Addressing these risks and challenges effectively will be crucial for Zimmer Biomet's continued growth and market leadership in the coming years. Continuous strategic evaluation and risk management practices will play an essential role in navigating this landscape.
Revenue & Expenses Breakdown
Zimmer Biomet Holdings Inc
Balance Sheet Decomposition
Zimmer Biomet Holdings Inc
Current Assets | 4.9B |
Cash & Short-Term Investments | 569m |
Receivables | 1.5B |
Other Current Assets | 2.8B |
Non-Current Assets | 16.9B |
PP&E | 2.1B |
Intangibles | 13.6B |
Other Non-Current Assets | 1.2B |
Current Liabilities | 3.6B |
Accounts Payable | 322.4m |
Other Current Liabilities | 3.2B |
Non-Current Liabilities | 5.8B |
Long-Term Debt | 4.7B |
Other Non-Current Liabilities | 1B |
Earnings Waterfall
Zimmer Biomet Holdings Inc
Revenue
|
7.6B
USD
|
Cost of Revenue
|
-2.1B
USD
|
Gross Profit
|
5.5B
USD
|
Operating Expenses
|
-3.9B
USD
|
Operating Income
|
1.6B
USD
|
Other Expenses
|
-468.1m
USD
|
Net Income
|
1.1B
USD
|
Free Cash Flow Analysis
Zimmer Biomet Holdings Inc
USD | |
Free Cash Flow | USD |
In Q3, Zimmer Biomet achieved 4% sales growth, marking 11 consecutive quarters of mid-single-digit growth. Despite ERP challenges affecting shipments, the impact is now estimated at 60-80 basis points, down from 100. The company expects 2024 revenue growth of 3.5%-4% due to currency fluctuations and a pricing outlook ranging from flat to +50 basis points. Adjusted earnings per share for 2024 is forecasted between $7.95 and $8.05, reflecting strong operational margins around 26.3%. With 50 significant product launches ahead, Zimmer Biomet is poised for sustainable growth, particularly across its Hips and S.E.T. segments.
What is Earnings Call?
ZBH Profitability Score
Profitability Due Diligence
Zimmer Biomet Holdings Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Zimmer Biomet Holdings Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
ZBH Solvency Score
Solvency Due Diligence
Zimmer Biomet Holdings Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Zimmer Biomet Holdings Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZBH Price Targets Summary
Zimmer Biomet Holdings Inc
According to Wall Street analysts, the average 1-year price target for ZBH is 125.78 USD with a low forecast of 108.07 USD and a high forecast of 152.25 USD.
Dividends
Current shareholder yield for ZBH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ZBH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 19,500 full-time employees. The company went IPO on 2001-07-25. The firm is engaged in the design, manufacture and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and thoracic (CMFT) products; dental implants, and related surgical products. The firm's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The company operates through four segments: Americas Orthopedics, Europe, Middle East and Africa (EMEA), Asia Pacific, and Americas Spine and Global Dental. Its knee brands include Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. Its S.E.T. brands include JuggerKnot Soft Anchor System, Gel-One1 Cross-linked Hyaluronate, Comprehensive Shoulder and others.
Contact
IPO
Employees
Officers
The intrinsic value of one ZBH stock under the Base Case scenario is 152.24 USD.
Compared to the current market price of 108.41 USD, Zimmer Biomet Holdings Inc is Undervalued by 29%.